Kidney disease biotech NephroGenex files for a $47 million IPO

By
A A A

NephroGenex, a clinical-stage biotech developing treatments for kidney disease, filed on Monday with the SEC to raise up to $47 million in an initial public offering. The Research Triangle Park, NC-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol NRX. NephroGenex initially filed confidentially on November 8, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: NRX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Freshman Finance 101
Freshman Finance 101                
Spot the Dropout RRC
Spot the Dropout RRC                
Power on/Power Off
Power on/Power Off                  

Stocks

Referenced

67%

Most Active by Volume

63,684,065
  • $16.34 ▼ 0.12%
57,325,780
  • $10.64 ▲ 1.33%
54,257,596
  • $112.76 ▼ 0.47%
40,862,548
  • $5.86 ▲ 1.38%
40,102,880
  • $28.54 ▲ 0.42%
36,273,867
  • $104.31 ▼ 1.24%
36,195,718
  • $13.87 ▲ 0.95%
35,675,931
  • $10.40 ▲ 0.97%
As of 8/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com